OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:261579
Who is this for?
Show terms as
8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Blepharophimosis-epicanthus inversus-ptosis (BPES) due to copy number variations is an obsolete Orphanet entry (Orphanet code 261579) that was previously used to classify cases of Blepharophimosis-Ptosis-Epicanthus Inversus Syndrome (BPES) specifically caused by chromosomal copy number variations (deletions or duplications) involving the FOXL2 gene region on chromosome 3q23. This condition has since been reclassified and merged into the broader BPES entity. BPES is a rare congenital condition primarily affecting the eyes and eyelids, characterized by four major features: blepharophimosis (narrowing of the horizontal eyelid opening), ptosis (drooping of the upper eyelids), epicanthus inversus (skin folds arising from the lower eyelids), and telecanthus (increased distance between the inner corners of the eyes). BPES exists in two forms: Type I, which includes premature ovarian insufficiency leading to female infertility, and Type II, which involves only the eyelid features without ovarian dysfunction. In cases attributed to copy number variations, the genetic mechanism involves deletions or duplications encompassing or disrupting the FOXL2 gene or its regulatory regions, rather than point mutations within the gene itself. The condition is typically inherited in an autosomal dominant pattern, though de novo copy number changes can also occur. Management of BPES generally involves surgical correction of the eyelid abnormalities, usually performed in early childhood to improve vision and cosmetic appearance. For women with Type I BPES, reproductive counseling and fertility management may be necessary. Because this Orphanet entry is now obsolete, patients and clinicians should refer to the main BPES classification (Orphanet code 126) for current clinical and genetic information.

Also known as:

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Nov 2021

Cytalux: FDA approved

As an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations community →

No specialists are currently listed for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources

Cytalux

On Target Laboratories, LLC

Cytalux — Contact On Target Laboratories, LLC

Unverified — confirm before calling
Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variationsForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations.

Start the conversation →

Latest news about OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations

No recent news articles for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations

What is OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations?

Blepharophimosis-epicanthus inversus-ptosis (BPES) due to copy number variations is an obsolete Orphanet entry (Orphanet code 261579) that was previously used to classify cases of Blepharophimosis-Ptosis-Epicanthus Inversus Syndrome (BPES) specifically caused by chromosomal copy number variations (deletions or duplications) involving the FOXL2 gene region on chromosome 3q23. This condition has since been reclassified and merged into the broader BPES entity. BPES is a rare congenital condition primarily affecting the eyes and eyelids, characterized by four major features: blepharophimosis (narr

How is OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations inherited?

OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations typically begin?

Typical onset of OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations is neonatal. Age of onset can vary across affected individuals.

What treatment and support options exist for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations?

1 patient support program are currently tracked on UniteRare for OBSOLETE: Blepharophimosis-epicanthus inversus-ptosis due to copy number variations. See the treatments and support programs sections for copay assistance, eligibility, and contact details.